The effect of the Medicare Part D benzodiazepine exclusion on the utilization patterns of benzodiazepines and substitute medications

Research in Social and Administrative Pharmacy

Volumn 10, Issue 2, 2014, Pages 438-447

  Chen, Yu Chieh ^a   Kreling, David H ^b  

^a MANCHESTER UNIVERSITY   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Benzodiazepines; Coverage exclusion; Medicare; Switching patterns

Indexed keywords

BENZODIAZEPINE DERIVATIVE;

AGED; ARTICLE; COVERAGE EXCLUSION; DRUG SUBSTITUTION; DRUG UTILIZATION; FEMALE; HUMAN; INSURANCE; MALE; MEDICARE; STATISTICS; SWITCHING PATTERNS; UNITED STATES; VERY ELDERLY;

BENZODIAZEPINES; COVERAGE EXCLUSION; MEDICARE; SWITCHING PATTERNS;

AGED; AGED, 80 AND OVER; BENZODIAZEPINES; DRUG SUBSTITUTION; DRUG UTILIZATION; FEMALE; HUMANS; INSURANCE COVERAGE; MALE; MEDICARE PART D; UNITED STATES;

EID: 84896732511     PISSN: 15517411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sapharm.2013.06.008     Document Type: Article

References (36)

1. Kaiser Family Foundation Fact Sheet - The Medicare Prescription Drug Benefit 2009.
2. Center for Medicare & Medicaid Service Medicare prescription drug benefit, final rule. Fed Regist 2005, 70:4194-4585.
3. Bambauer K.Z., Sabin J.E., Soumerai S.B. The exclusion of benzodiazepine coverage in Medicare: simple steps for avoiding a public health crisis. Psychiatr Serv 2005, 56:1143-1146.
4. Stefanacci R.G. The cost of being excluded: impact of excluded medications under Medicare Part D on nursing home residents. J Am Med Dir Assoc 2005, 6:415-420.
5. Briesacher B., Soumerai S., Field T., Fouayzi H., Gurwitz J. Medicare Part D's exclusion of benzodiazepines and fracture risk in nursing homes. Arch Intern Med 2010, 170:693.
6. Medicare Rights Center Critical Coverage: Benzodiazepines Under Medicare Part D June 2005.
7. Shader R.I., Greenblatt D.J. Use of benzodiazepines in anxiety disorder. New Engl J Med 1993, 328:1398-1405.
8. Haw C., Stubbs J. Benzodiazepines-a necessary evil? A survey of prescribing at a specialist UK psychiatric hospital. J Psychopharmacol 2007, 21(6):645-649.
9. Nelson J., Chouinard G. Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal. Canadian Society for Clinical Pharmacology. Can J Clin Pharmacol 1999, 6:69.
10. Möller H.J. Effectiveness and safety of benzodiazepines. J Clin Psychopharmacol 1999, 19:2S.
11. Ashton H. Guidelines for the rational use of benzodiazepines: when and what to use. Drugs 1994, 48:25-40.
12. Salzman C. Benzodiazepine Dependence, Toxicity, and Abuse: A Task Force Report of the American Psychiatric Association 1990, APA, Washington, DC.
13. Nelson R. Estimates of Benzodiazepine Use, Doses, and Duration of Use; Data on Seizures and Other Reported Withdrawal. Denominator of Exposure-How Many Individuals Are Exposed to Benzodiazepines (Unpublished Manuscript). Washington, DC: US Food and Drug Administration;1987.
14. World Health Organization WHO Model List of Essential Medicines 2010, Available at:. http://www.who.int/medicines/publications/essentialmedicines/Updated_sixteenth_adult_list_en.pdf.
15. Beers M.H. Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. Arch Intern Med 1997, 157(14):1531-1536.
16. National Pharmaceutical Council Pharmaceutical Benefits Under State Medical Assistance Programs 2003, Available at:. http://www.scribd.com/doc/8220748/Pharmaceutical-Benefits-Under-State-Medical-Assistance-Programs-2003.
17. Ashton H. Guidelines for the rational use of benzodiazepines. Drugs 1994, 48(1):25-40.
18. Longo L., Johnson B. Addiction: part I. Benzodiazepines-side effects, abuse risk and alternatives. Am Fam Physician 2000, 61:2121-2128.
19. Ross-Degnan D., Simoni-Wastila L., Brown J.S., et al. A controlled study of the effects of state surveillance on indicators of problematic and non-problematic benzodiazepine use in a Medicaid population. Int J Psychiatry Med 2004, 34:103-123.
20. Cook J.M., Marshall R., Masci C., Coyne J.C. Physicians' perspectives on prescribing benzodiazepines for older adults: a qualitative study. J Gen Intern Med 2007, 22:303-307.
21. Cook J.M., Biyanova T., Masci C., Coyne J.C. Older patient perspectives on long-term anxiolytic benzodiazepine use and discontinuation: a qualitative study. JGen Int Med 2007, 22:1094-1100.
22. Chen H., Nwangwu A., Aparasu R., Essien E., Sun S., Lee K. The impact of Medicare Part D on psychotropic utilization and financial burden for community-based seniors. Psychiatr Serv 2008, 59:1191-1197.
23. Ong M.K., Zhang L., Xu H., Azocar F., Ettner S.L. Medicare Part D benzodiazepine exclusion and use of psychotropic medication by patients with new anxiety disorders. Psychiatr Serv 2012, 63:637-642.
24. Simon G.E., Vonkorff M., Barlow W., Pabiniak C., Wagner E. Predictors of chronic benzodiazepine use in a health maintenance organization sample. JClin Epidemiol 1996, 49:1067-1073.
25. Johnell K., Fastbom J. The use of benzodiazepines and related drugs amongst older people in Sweden: associated factors and concomitant use of other psychotropics. Int J Geriatr Psychiatry 2009, 24:731-738.
26. Stowell K.R., Chang C.C.H., Bilt J.V., Stoehr G.P., Ganguli M. Sustained benzodiazepine use in a community sample of older adults. J Am Geriatr Soc 2008, 56:2285-2291.
27. Cheng J.S., Huang W.F., Lin K.M., Shih Y.T. Characteristics associated with benzodiazepine usage in elderly outpatients in Taiwan. Int J Geriatr Psychiatry 2008, 23:618-624.
28. Gray S., Eggen A., Blough D., Buchner D., LaCroix A. Benzodiazepine use in older adults enrolled in a health maintenance organization. Am J Geriatr Psych 2003, 11:568.
29. Fishman P., Goodman M., Hornbrook M., Meenan R., Bachman D., O'Keeffe Rosetti M. Risk adjustment using automated ambulatory pharmacy data: the RxRisk model. Med Care 2003, 41:84.
30. Von Korff M., Wagner E., Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992, 45:197-203.
31. Shrank W.H., Patrick A.R., Pedan A., et al. The effect of transitioning to Medicare Part D drug coverage in seniors dually eligible for Medicare and Medicaid. J Am Geriatr Soc 2008, 56(12):2304-2310.
32. Cote B.R., Petersen E.A. Impact of therapeutic switching in long-term care. Am J Manag Care 2008, 14.
33. Gleason P., Schulz R., Smith N., et al. Correlates and prevalence of benzodiazepine use in community-dwelling elderly. J Gen Int Med 1998, 13:243-250.
34. Bartlett G., Abrahamowicz M., Grad R., Sylvestre M.P., Tamblyn R. Association between risk factors for injurious falls and new benzodiazepine prescribing in elderly persons. BMC Fam Pract 2009, 10:1.
35. Olfson M., Pincus H.A. Use of benzodiazepines in the community. Arch Intern Med 1994, 154:1235.
36. Kennedy J., Coyne J., Sclar D. Drug affordability and prescription noncompliance in the United States: 1997-2002. Clin Ther 2004, 26:607-614.